Endosc Int Open 2016; 04(06): E709-E714
DOI: 10.1055/s-0042-106959
Original article
© Georg Thieme Verlag KG Stuttgart · New York

Gastric ulcers: malignancy yield and risk stratification for follow-up endoscopy

Christian P Selinger
1   Department of Gastroenterology, Leeds Teaching Hospitals NHS Trust, Leeds, UK
2   University of Leeds, Leeds, UK
,
Rebecca Cochrane
1   Department of Gastroenterology, Leeds Teaching Hospitals NHS Trust, Leeds, UK
,
Sangeetha Thanaraj
1   Department of Gastroenterology, Leeds Teaching Hospitals NHS Trust, Leeds, UK
,
Anita Sainsbury
1   Department of Gastroenterology, Leeds Teaching Hospitals NHS Trust, Leeds, UK
,
Venkat Subramanian
1   Department of Gastroenterology, Leeds Teaching Hospitals NHS Trust, Leeds, UK
2   University of Leeds, Leeds, UK
,
Simon Everett
1   Department of Gastroenterology, Leeds Teaching Hospitals NHS Trust, Leeds, UK
› Author Affiliations
Further Information

Publication History

submitted 07 October 2015

accepted after revision 11 April 2016

Publication Date:
19 May 2016 (online)

Background and study aim: Malignant change can occur in gastric ulcer but guideline recommendations for follow-endoscopy (FU-OGD) are conflicting. This study aims to determine rate of malignancy and need for follow-up for gastric ulcers.

Patients and methods: Patients with a first diagnosis of gastric ulcer between January 2012 and September 2013 were studied by analyzing endoscopic assessments, dysplasia, and malignancy yield and the influence of risk factors on the likelihood of benign disease.

Results: In a cohort of 432 patients with gastric ulcer (53 % male, mean age 65 years) dysplasia or neoplasia were found in 27 (19 adenocarcinomas, 2 cases of dysplasia, 5 lymphomas, 1 melanoma; malignancy yield 6 %). Twenty-five (93 %) cases were diagnosed on first biopsy. The cancer yield of FU-OGD after initially benign biopsy was 0.9 %. Binary logistic regression analysis revealed that endoscopically benign appearance (odds ratio 0.004 95 % CI 0 – 0.576; P = 0.029), benign histology on first biopsy (odds ratio 0 95 % CI 0 – 0.39; P = 0.011) and lower number of ulcers (odds ratio 0.22 (95 % CI 0.05 – 0.99); P = 0.049) were independent predictors of benign disease. All dysplastic and neoplastic cases would have been identified by a combination of initial biopsies plus repeat endoscopy with further biopsies for endoscopically suspicious appearances.

Conclusions: In this large cohort 6 % of gastric ulcers were found to be malignant, highlighting the need for all gastric ulcers to be biopsied. The cancer yield of FU-OGD after benign biopsies was low. We have demonstrated that the combination of benign index histology and no endoscopic suspicion of malignancy can predict benign disease. We recommend that all gastric ulcers to be biopsied. Risk stratification could potentially reduce need for FU-OGD.

 
  • References

  • 1 Kuipers EJ, Thijs JC, Festen HP. The prevalence of Helicobacter pylori in peptic ulcer disease. Aliment Pharmacol Ther 1995; 9 (Suppl. 02) 59-69
  • 2 Bustamante M, Devesa F, Borghol A et al. Accuracy of the initial endoscopic diagnosis in the discrimination of gastric ulcers: is endoscopic follow-up study always needed?. J Clin Gastroenterol 2002; 35: 25-28
  • 3 Lv SX, Gan JH, Ma XG et al. Biopsy from the base and edge of gastric ulcer healing or complete healing may lead to detection of gastric cancer earlier: an 8 years endoscopic follow-up study. Hepatogastroenterol 2012; 59: 947-950
  • 4 Amorena Muro E, Borda Celaya F, Martínez-Peñuela Virseda JM et al. [Analysis of the clinical benefits and cost-effectiveness of performing a systematic second-look gastroscopy in benign gastric ulcer]. Gastroenterol Hepatol 2009; 32: 2-8
  • 5 Mañas MD, Domper A, Albillos A et al. Endoscopic follow-up of gastric ulcer in a population at intermediate risk for gastric cancer. Rev Esp Enferm Dig 2009; 101: 317-324
  • 6 National Institue for Health and Care Excellence. Dyspepsia: Management of dyspepsia in adults in primary care. In: excellence NIfHaC (ed) NICE clinical guideline 17 2004;
  • 7 National Institue for Health and Care Excellence. Dyspepsia and gastro-oesophageal reflux disease. NICE clinical guideline 184 2014;
  • 8 Banerjee S, Cash BD, Dominitz JA et al. The role of endoscopy in the management of patients with peptic ulcer disease. Gastrointest Endosc 2010; 71: 663-668
  • 9 Uemura N, Sugano K, Hiraishi H et al. Risk factor profiles, drug usage, and prevalence of aspirin-associated gastroduodenal injuries among high-risk cardiovascular Japanese patients: the results from the MAGIC study. J Gastroenterol 2014; 49: 814-824
  • 10 [Anonymous]. Defining Research. In: Health Research Authority; London: 2009
  • 11 Schlemper RJ, Riddell RH, Kato Y et al. The Vienna classification of gastrointestinal epithelial neoplasia. Gut 2000; 47: 251-255
  • 12 Choi Y, Choi HS, Jeon WK et al. Optimal number of endoscopic biopsies in diagnosis of advanced gastric and colorectal cancer. J Korean Med Sci 2012; 27: 36-39
  • 13 Graham DY, Schwartz JT, Cain GD et al. Prospective evaluation of biopsy number in the diagnosis of esophageal and gastric carcinoma. Gastroenterology 1982; 82: 228-231
  • 14 Naylor GM, Gotoda T, Dixon M et al. Why does Japan have a high incidence of gastric cancer? Comparison of gastritis between UK and Japanese patients. Gut 2006; 55: 1545-1552
  • 15 Namekata T, Miki K, Kimmey M et al. Chronic atrophic gastritis and Helicobacter pylori infection among Japanese Americans in Seattle. American journal of epidemiology 2000; 151: 820-830
  • 16 [Anonymous]. 2011 Census: Population Estimates for the United Kingdom. In: Statistics OfN (ed). London: 2011
  • 17 Yeh JM, Ho W, Hur C. Cost-effectiveness of endoscopic surveillance of gastric ulcers to improve survival. Gastrointest Endosc 2010; 72: 33-43
  • 18 Wu CY, Kuo KN, Wu MS et al. Early Helicobacter pylori eradication decreases risk of gastric cancer in patients with peptic ulcer disease. Gastroenterology 2009; 137: 1641-1648
  • 19 Tsukuma H, Oshima A, Narahara H et al. Natural history of early gastric cancer: a non-concurrent, long term, follow up study. Gut 2000; 47: 618-621
  • 20 Devane C. Living after diagnosis: Median cancer survival times. In: Macmillan Cancer Support as accessed on 13/01/2016. http://www.macmillan.org.uk/Documents/AboutUs/Newsroom/LivingAfterCancerMedianCancerSurvivalTimes.pdf